Welcome to our dedicated page for Cormedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CorMedix Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company commercializing DefenCath and a broader portfolio of institutional-care specialty pharmaceuticals. Form 8-K reports cover operating results, financial condition, corporate presentations, material-event disclosures, clinical or regulatory updates and business developments following the completed Melinta Therapeutics acquisition.
Proxy statements describe shareholder voting matters, board and governance practices, equity incentive plan proposals, certificate of incorporation matters and preferred-stock voting provisions. Acquisition-related amendments include financial statements of the acquired business and pro forma financial information, while the company’s securities disclosures identify CRMD common stock listed on the Nasdaq Global Market.
CorMedix Inc. reported a change in its executive leadership structure. The Board appointed current Chief Operating Officer Elizabeth Hurlburt to a newly created role of Chief Operating and Commercial Officer, giving her oversight of all commercial functions along with medical affairs, regulatory and clinical. She will continue to report to Chairman and CEO Joseph Todisco. As part of this restructuring, Michael Seckler has left the company.
CorMedix Inc. changed its independent registered public accounting firm, appointing Ernst & Young LLP (EY) as auditor for the fiscal year ending December 31, 2026. The Audit Committee dismissed CBIZ CPAs P.C. on June 25, 2026. CBIZ’s report on the 2025 financial statements contained no adverse opinion or qualification. The only reportable event during CBIZ’s tenure was a previously disclosed material weakness in internal control over financial reporting related to timely review of significant, non-routine transactions, first reported in the 2025 Form 10-K filed March 5, 2026. CBIZ has been authorized to respond fully to EY about this matter and has provided a letter to the SEC agreeing or commenting on the company’s statements.
CorMedix Inc. reported results from its 2026 annual meeting of stockholders held on June 23, 2026. Stockholders elected all seven director nominees, each receiving more votes for than withheld. They also approved, on a non-binding advisory basis, 2025 compensation for named executive officers and ratified CBIZ CPAs P.C. as independent auditor for the 2026 fiscal year.
Several proposed amendments to the company’s charter did not receive sufficient support, including ratification of Certificate of Designation amendments, technical charter changes, updates to class voting on preferred stock terms, an exclusive forum provision, and expanded officer liability protections permitted by Delaware law.
CorMedix Inc. amendment reports that SHAIBATALHAMD AYMEN ABDALKADER beneficially owns 4,618,511 shares of Common Stock, representing 5.89% of the class, with sole voting and sole dispositive power over those shares. The filing is signed and dated 06/12/2026 as Amendment No. 5.
CorMedix Inc. ownership disclosure: Aymen Abdalkader Shaibata (a Saudi Arabia citizen) reports beneficial ownership of 4,618,511 shares of Common Stock, representing 5.89% of the class. The filing is an amendment to a Schedule 13G/A and is signed on 06/12/2026.
The form lists voting and dispositive power as sole for 4,618,511 shares. The filing provides a snapshot of a single investor's position rather than a transaction record.
CorMedix Inc. reported that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior district court judgment in patent litigation over MINOCIN® for Injection. The court agreed that Nexus Pharmaceuticals’ proposed generic minocycline product infringes two CorMedix patents and rejected Nexus’s invalidity challenge.
The Federal Circuit also upheld a permanent injunction that prevents Nexus from marketing its generic minocycline product before the MINOCIN® patents expire. This decision strengthens the intellectual property protection around CorMedix’s intravenous minocycline reformulation, an antibiotic used primarily in hospital and acute care settings.
CorMedix Inc. reports a Schedule 13G/A showing Deep Track-affiliated holders beneficially own 6,274,076 shares of common stock. The filing states this equals 7.94% of the class based on March 2, 2026 outstanding shares of 79,050,395. The joint filing names Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin and indicates shared voting and dispositive power over the reported shares.
CorMedix Inc. reported strong first-quarter 2026 results, with net revenue of $127.4 million and net income of $38.6 million. Adjusted EBITDA reached $70.0 million, reflecting profitability after integrating the Melinta acquisition.
DefenCath generated $97.5 million of net revenue, helped by higher outpatient dialysis use and a one-time $9.0 million favorable change in sales allowance estimates, while the acquired Melinta portfolio contributed $29.9 million. The company raised full-year 2026 guidance to $325–$345 million in net revenue and $115–$135 million in adjusted EBITDA.
CorMedix also highlighted positive Phase III topline results from the ReSPECT trial of REZZAYO for prophylaxis in allogeneic stem cell transplant patients and progress in a Phase 3 taurolidine/heparin study in TPN patients. Cash and short-term investments were $178.1 million as of March 31, 2026, supporting continued growth investments.